Abstract
The aim of this placebo-controlled, double-blind randomized study was to evaluate the duration of the effect of once-daily administration of irbesartan in patients with essential hypertension. After a placebo run-in baseline period (of 2–4 weeks), 79 patients were randomized to either irbesartan (one 100 mg tablet per day) or placebo, for 6 weeks. The primary outcome was the reduction in the mean 24-h blood pressure (BP) as assessed by ambulatory BP monitoring under standardized conditions. Seventy-six patients completed the study protocol. In the irbesartan group, the average reductions in 24-h systolic and diastolic BPs were 5.8 and 3.4 mmHg, respectively (95% confidence interval: 3.2–8.4/1.6–5.1 mmHg), and in the placebo group, they were –1.7 and –0.5 mmHg, respectively (95% confidence interval: −4.3 to 1.0/−1.8 to 0.7 mmHg). There were statistically significant differences in the average reductions of 24-h BP (7.5/3.9 mmHg, p<0.001), daytime BP (8.6/4.0 mmHg, p<0.001) and nighttime BP (6.1/3.4 mmHg, p<0.05) as well as casual BP (9.0/5.0 mmHg, p<0.001). The trough/peak (T/P) ratios for the systolic and diastolic BPs were 0.84 and 0.78, respectively, in the irbesartan group. The incidence of adverse events was similar in both groups. The results showed that irbesartan administered 100 mg once daily was well tolerated in the treatment of essential hypertension and was effective in producing sustained 24-h BP control.
Article PDF
References
Sytkowski PA, Kannel WB, D'Agostino RB : Changes in risk factors and decline in mortality from cardiovascular disease: the Framingham Heart Study. N Engl J Med 1990; 322: 1635–1641.
Staessen J, Li Y, Thijs L : Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens Res 2005; 28: 385–407.
Imai Y, Abe K, Sasaki S, et al: Determination of clinical accuracy and nocturnal blood pressure pattern by new portable device for monitoring indirect ambulatory blood pressure. Am J Hypertens 1990; 3: 293–301.
Imai Y, Sasaki S, Minami N, et al: The accuracy and performance of the A&D TM2421, a new ambulatory blood pressure monitoring device based on the cuff-oscillometric method and the Korotkoff sound technique. Am J Hypertens 1992; 5: 719–726.
Kuwajima I, Nishinaga M, Kanamura A : The accuracy and clinical performance of a new compact ambulatory blood pressure monitoring device, the ES-H531. Am J Hypertens 1998; 11: 1328–1333.
Imai Y : Prognostic significance of ambulatory blood pressure. Blood Press Monit 1999; 4: 249–256.
Principles for Clinical Evaluation of New Antihypertensive Drugs. Notification No. 0128001 of the Evaluation and Licensing Division, PFSB, dated January 28, 2002. Iyakuhin Kenkyu 2002; 33: 546–550 ( in Japanese).
Yoshinaga K : A late phase II clinical study of irbesartan capsules, an angiotensin II receptor antagonist, in patients with essential hypertension single—agent therapy/monotherapy—. J Clin Therap Med 2008; 24: 345–366 ( in Japanese).
Fogari R, Ambrosoli S, Corradi L, et al: 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens 1997; 15: 1511–1518.
Shimada K, Imai Y, Kuwajima I, et al: Guidelines for Diagnosis and Treatment of Cardiovascular Disease (1998–1999 yearly report of the research group), Usage Guidelines for 24-hour Blood Pressure Monitoring Devices (ABPM). Jpn Circ J 2000; 64 ( Suppl V): 1207–1248 ( in Japanese).
Katarzyna P, Bogna P, Marek K, et al: Clinical evaluation of 24 h ambulatory monitoring of blood pressure under various environmental conditions (home and work versus hospital). Blood Press Monit 1998; 3: 289–294.
Kawano Y, Ando K, Matsuura H, et al: Report of the Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension: (1) Rationale for salt restriction and salt-restriction target level for the management of hypertension. Hypertens Res 2007; 30: 879–886.
Morgan T, Anderson A : A comparison of candesartan, felodipine and their combination in the treatment elderly patients with systolic hypertension. Am J Hypertens 2002; 15: 544–549.
Kojima S, Kawano Y, Yoshitomi Y, et al: Comparison of first-line antihypertensive drugs by a randomized crossover method—a preliminary report. Hypertens Res 1995; 18: 303–305.
Eguchi K, Kario K, Hoshide Y, et al: Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients. Am J Hypertens 2004; 17: 112–117.
Miura K, Iwao H : Clinical pharmacology of angiotensin receptor blockers: characteristics of pharmacokinetics and pharmacological actions. Prog Med 2000; 20: 1235–1242 ( in Japanese).
Miyazaki M : Overview of pharmacology of angiotensin receptor blockers. J Blood Press 2005; 12: 21–26 ( in Japanese).
Mancia G, Korlipara K, van Rossum P, Villa G, Silvert B : An ambulatory blood pressure monitoring study of the comparable antihypertensive efficacy of two angiotensin receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7: 135–142.
Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J : Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283–291.
Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J : Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007; 25: 1327–1336.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kawano, Y., Sato, Y. & Yoshinaga, K. A Randomized Trial of the Effect of an Angiotensin II Receptor Blocker SR47436 (Irbesartan) on 24-Hour Blood Pressure in Patients with Essential Hypertension. Hypertens Res 31, 1753–1763 (2008). https://doi.org/10.1291/hypres.31.1753
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.1753